Lexicon Pharmaceuticals Inc (LXRX)vsNovartis AG ADR (NVS)
LXRX
Lexicon Pharmaceuticals Inc
$2.00
-0.99%
HEALTHCARE · Cap: $1.01B
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 136612% more annual revenue ($56.69B vs $41.47M). NVS leads profitability with a 22.5% profit margin vs -147.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).
LXRX
Avoid16
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LXRX.
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -12.9% — below average capital efficiency
Revenue declined 97.6%
Earnings declined 63.4%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LXRX
LXRX has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : LXRX
The primary concerns for LXRX are Market Cap, Return on Equity, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
LXRX profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
LXRX carries more volatility with a beta of 1.03 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 16/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lexicon Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?